MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5

Exclusion Criteria

• •Known sensitivity to EPOETIN ALFA HEXAL® or any other ESA.
• •Solid or hematological neoplasia being treated with chemotherapy.
• •Treatment with any myelosuppressant medications.
• •Blood transfusion dependency.
• •History of pure red cell aplasia.
• •Bleeding episode in 30 days prior to enrollment.
• •Orthopaedic surgery in 30 days prior to enrollment.
• •Patients with several medical condition(s) that in view of the investigator prohibits participation in the study.
• •Patients with willfully negligent nonadherence to their haemodialysis, medication, nutrition, and/or other recommended treatment regimens.
• •Use of any investigational agent in the 30 days prior to enrollment.
• •Women of childbearing potential not using the contraception method(s) described above.
• •Women who are breastfeeding.